On December 11, 2018, Meghan FitzGerald notified Concert Pharmaceuticals, Inc. of her decision to resign as a member of the Board of 18 Directors of the Company, effective as of December 11, 2018. Ms. FitzGerald works in private equity and one of her new portfolio companies, which is in the business of investing in biotechnology companies, prohibits Ms. FitzGerald from sitting on the Board in order to avoid any potential conflicts of interest. Ms. FitzGerald's resignation is not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.